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Abstract— Parameters of physiological models of 
glucose-insulin regulation in type 1 diabetes have previously 
been estimated using data collected over short periods of time 
and lack the quantification of day-to-day variability. We 
developed a new hierarchical model to relate subcutaneous 
insulin delivery and carbohydrate intake to continuous glucose 
monitoring over 12 weeks while describing day-to-day 
variability. Sensor glucose data sampled every 10 min, insulin 
aspart delivery and meal intake were analyzed from 8 adults 
with type 1 diabetes (male/female 5/3, age 39.9±9.5 years, BMI 
25.4±4.4 kg/m2, HbA1c 8.4±0.6%) who underwent a 12-week 
home study of closed-loop insulin delivery.  A compartment 
model comprised five linear differential equations; model 
parameters were estimated using the Markov chain Monte 
Carlo approach within a hierarchical Bayesian model 
framework. Physiologically plausible a posteriori distributions 
of model parameters including insulin sensitivity, time-to-peak 
insulin action, time-to-peak gut absorption, and carbohydrate 
bioavailability, and good model fit were observed. Day-to-day 
variability of model parameters was estimated in the range of 
38 to 79% for insulin sensitivity and 27 to 48% for time-to-peak 
of insulin action. In conclusion, a linear Bayesian hierarchical 
approach is feasible to describe a 12-week glucose-insulin 
relationship using conventional clinical data. The model may 
facilitate in silico testing to aid the development of closed-loop 
insulin delivery systems.  
Index Terms—Artificial pancreas, Bayesian parameter 
estimation, Hierarchical model, Simulation, Type 1 diabetes  
I. INTRODUCTION 
YPE 1 diabetes (T1D) is characterized by autoimmune 
destruction of the pancreatic β-cells secreting insulin in 
health and leads to a lifelong dependency on exogenous 
insulin to prevent the development of ketoacidosis, coma and 
death [1-3]. Maintaining glycemic level within the near-normal 
target range by applying individualized insulin dosing regimens 
is a key factor in reducing the risk of long-term and acute 
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diabetes micro- and macrovascular complications and delaying 
the progression of the disease. As glucose excursions in T1D 
are affected by numerous factors including diet, exercise, stress 
with considerable day-to-day and between-subject variability, 
achieving and maintaining glycemic target on a daily basis is 
challenging despite guidance by experienced healthcare 
professionals.  
Closed-loop glucose control referred to as ‘the artificial 
pancreas’ is an emerging technology that offers automated, 
glucose responsive insulin delivery. The extracorporeal device 
comprises a continuous glucose monitoring (CGM) system, an 
insulin pump and a control algorithm which directs insulin 
delivery by the insulin pump based on real-time CGM values. 
The artificial pancreas has recently been evaluated in longer 
term home studies in children and adults with T1D 
demonstrating improved glycemic control and a reduced 
hypoglycemia risk compared to conventional 
sensor-augmented pump therapy [4-6]. 
The safety and efficacy of the control algorithm and system 
level performance requires rigorous assessments. Testing via 
computer simulations may accelerate the development and 
saves resources compared to clinical testing [7]. An in silico 
simulation environment for T1D encompasses as a key feature 
a mathematical model of glucose-insulin regulation in T1D 
[7-9]. Numerous gluco-regulatory models of varying 
complexity have been proposed [10-14]. However, existing 
models are commonly limited by the fact that glucose 
excursions are modelled over relatively short periods of time, 
from several hours up to two days, and lack the ability to 
describe evidence-based day-to-day variability. As closed-loop 
insulin delivery systems have entered the stage of long-term 
home trials [15], a simulation model which produces realistic 
multi-day glycemic excursions is highly desirable to describe 
day-to-day variability of responses to insulin, meals and other 
relevant factors.  
Here we present a model of glucose-insulin regulation 
developed with the aim to fulfill such requirements. Major 
motivation was the availability of a unique dataset comprising 
continuously measured sensor glucose, meals and insulin data 
over 12 weeks. The data were collected in adults with T1D who 
used 24/7 closed-loop insulin delivery for 12 weeks in 
free-living home settings [4]. The multi-day datasets allowed us 
to impose a hierarchical model structure to capture day-to-day 
variability. Individual physiological parameters were estimated 
using a full Bayesian approach adopting the Markov chain 
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Monte Carlo (MCMC) technique. Having identified model 
parameters and to demonstrate the model’s ability to predict 
glucose excursions we carried out computer simulations of an 
unrelated clinical trial to support model validity [16]. 
By capturing both between-subject and day-to-day 
variability of physiological parameters, the presented model 
could be implemented in an in silico testing environment to aid 
the development of closed-loop insulin delivery systems. 
II. METHODS 
The proposed model comprises five compartments and is 
used to fit CGM data collected in a 12-week long clinical study 
[4]. A hierarchical Bayesian framework is utilized for 
parameter estimation.  
A. Glucose-Insulin Model 
The glucose-insulin model comprises three sub-models 
describing insulin absorption and action, meal absorption 
dynamics and glucose dynamics. The model uses subcutaneous 
insulin delivery and carbohydrate intake as model input and 
continuous glucose monitoring as model as model output. 
1) Insulin Absorption and Action  
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=    (3) 
where x1 (t) and  x2 (t) represent the amount of effective insulin 
in the first and second insulin absorption compartment, 
respectively (U); uI (t) represents exogenous delivery rate of 
insulin aspart (U/h) at time t (immediate insulin bolus is 
modelled as a short burst insulin infusion); tmax,IA is the 
time-to-maximum of effective insulin concentration (min); X 
(t) is the concentration of effective insulin (mU/l); W  is 
subject’s body weight (kg); and MCRI is the metabolic 
clearance rate of effective insulin fixed at 0.017 (l/kg/min) as 
reported in [17].  
2) Meal Absorption Dynamics 
The meal absorption is represented by two compartments 
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where a1 (t) and a2 (t) represent carbohydrate amount in the 
first and second meal absorption compartment, respectively 
(g); uG (tj) represents the carbohydrate amount eaten at time tj 
(g); tmax,G is the time-of-maximum appearance rate of glucose 
(min); AG is the fractional bioavailability (unitless); VG is the 
plasma glucose pool size fixed at 0.16 (l/kg) as reported in [12]; 
UM (t) is the gut carbohydrate absorption rate with unit 




Fig. 1. Bayesian hierarchical analysis of the glucose-insulin regulation. Estimates of the day-level parameters SI, tmax,IA, Xb, tmax,G, AG, K and Gb were made in parallel 
with the subject-level mean and SD in one subject over N days. The advantage of Bayesian estimation is the possibility of ‘information flow’ between days since the 
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3) Glucose Dynamics 
The kinetics of the continuously monitored glucose 
concentration is represented by a single compartment:  
( )
( ( ) ) ( ) ( ( ) )I b M b
dG t
S X t X U t K G t G
dt
= − − + − −  (7) 
where G (t) is the blood glucose concentration (mmol/l); SI is 
the insulin sensitivity (mmol/l/min per mU/l); Xb represents the 
basal effective insulin concentration at which glucose level 
would be maintained constant (mU/l); Gb is the basal glucose 
level (mmol/l) and K the glucose self-regulation fractional rate 
(/min) which has an effect of self-regulating the glucose level 
towards Gb.  
  It is assumed that the insulin-dependent glucose utilization 
does not depend on plasma glucose concentration. This 
assumption is also used by Magdelaine et al. in their recent 
modelling work [11]. 
B. Closed-Form Solution  
The linearity of the system of ordinary differential equations 
(1)-(7) allows a closed-form solution to be obtained 
substantially speeding up inference. The description of the 
solution is presented in Online Supplementary Material (OSM) 
Appendix A. The solution is coded into the parameter 
estimation software, accelerating the estimation process when 
the Bayesian inference and Markov chain Monte Carlo 
(MCMC) methods are utilized (see section D).  
C. Experimental Data 
Conventionally collected clinical data including sensor 
glucose, insulin aspart delivery and meal intake were analyzed. 
The data were collected from 8 adults with type 1 diabetes 
(male/female 5/3, age 39.9±9.5 years, BMI 25.4±4.4 kg/m2, 
HbA1c 8.4±0.6%) who underwent a 12-week study of 
closed-loop insulin delivery in free-living home settings [4].  
The study protocol was approved by local ethics committee. 
All participants signed informed consent and the study was 
conducted in accordance with the Declaration of Helsinki.  
During closed-loop, the sensor glucose were sampled every 
10 min by FreeStyle Navigator II CGM system (Abbott 
Diabetes Care); basal insulin infusion rates on the study pump 
(Dana R Diabecare, Sooil) were automatically adjusted every 
12 min using a model-predictive-control algorithm [18] and 
real-time continuous glucose sensor levels; participants 
additionally administered prandial insulin using the standard 
pump bolus calculator which also recorded the carbohydrate 
content for each bolused meal as estimated by the subject.  
Data of individual days with amount of sensor glucose 
readings less than 85 out of 144 reads per day (<60%) were 
considered incomplete and excluded from the present analysis. 
D. Parameter Estimation 
For each subject, model parameters were estimated using the 
MCMC approach within a hierarchical Bayesian framework. 
 
1) Bayesian Hierarchical Analysis 
A multi-day dataset with up to 84 days per subject was used 
by the Bayesian hierarchical approach which incorporated 
vague prior information at the subject-level to estimate the 
model parameters. For each subject, estimates of the day-level 
parameters SI, tmax,IA, Xb, tmax,G, AG, K and Gb (one set of 
parameters per day; during the day parameters were assumed 
time invariant) were made in parallel with the subject-level 
mean and the coefficient of variation (CV) of day-to-day 
variability. Qualified day-level clinical data (see section C) 
collected from closed-loop insulin delivery were utilized. A 
schematic representation of the Bayesian hierarchical 
framework is shown in Fig. 1. A more detailed description of 
the Bayesian hierarchical approach is provided in OSM 
Appendix C. 
2) Prior Density Functions 
The Bayesian analysis utilizes prior distribution of model 
parameters. In principle, reliable prior knowledge for some of 
the parameters allows relatively strong prior distributions with 
tight variances to be applied. Generally, non-informative vague 
prior distributions are adopted for parameters of interest to 
allow clinical data to determine the posterior distributions [19]. 
In the present analysis, vague but proper prior information with 
a large variance was assigned to model parameters (OSM 
Appendix B). 
3) Implementation Details 
The parameter estimation was carried out using the Bayesian 
framework (OSM Appendix C). Following the model 
specification and assignment of prior distributions to unknown 
parameters, Bayesian statistical inference was applied to obtain 
posterior distributions of parameters. The WinBUGS software 
[20] using MCMC techniques [21] and Metropolis-Hasting 
algorithm [22] was utilized to draw samples from the target 
posterior distributions of unknown parameters. The WinBUGS 
extension ‘WBDev’ [23, 24] was used to implement the 
closed-form solution of the glucose-insulin regulation model 
into the statistical model. For the purposes of parameter 
estimation, the errors associated with the CGM measurements 
were assumed to be non-correlated normally distributed with 
zero mean and a coefficient of variation (CV) of 10%. 
For each parameter, a single Markov chain was analyzed 
with 4,000 samples (with thinning of 200 – equivalent to 
800,000 iterations in total), from which the first 2,000 samples 
were discarded as burn-in chains and the remaining 2,000 
samples were used for further analysis. The calculations were 
performed on a Microsoft Windows Server version 6.1. For 
each subject’s dataset, the generation of the chains with 4,000 
samples took approximately 70 hours. 
Further details of the Bayesian approach can be found in 
OSM Appendix C.  




A. Sample Fit 
A sample model fit to 12 days of CGM measurements is 
shown in Fig. 2, indicating the ability of the model to fit the 
data.  
B. Assessment of Model Fit 
Good unbiased model fit was obtained for all 8 datasets as 
demonstrated by the plot of weighted residuals associated with 
CGM measurements, see Fig. 3.  
 
 
Fig. 2. Model fit of CGM data in a sample subject Cam03 (Day 26 – Day 37 are shown). The black circles are CGM measurements, the red solid lines represent 
the median of model fit, and the blue dashed lines represent 95% credible intervals of model fit.   
 
TABLE I 
ESTIMATES OF SUBJECT-LEVEL AND POPULATION-LEVEL MODEL PARAMETERS 
 Parameter 
Subject tmax,IA (min) 
SI 
































































































































                           Subject-level mean (CV) over days and population parameter values (population CV) mean±SD are reported. 
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C. Parameter Estimates 
Posterior realizations of subject-level and day-level 
parameters demonstrated physiological plausibility. Parameter 
estimates of the subject-level mean and CV, and population 
mean±SD are reported in Table I. The estimated tmax,IA for 
insulin aspart at 78 min lies within the reported range of 30-90 
min [25]. The insulin sensitivity index SI was estimated at 
0.005 mmol/l/min per mU/l which is in accordance with 
published literature reporting 0.0005 /min per mU/l if at a 
glucose concentration of 10 mmol/l [26]. The basal effective 
insulin concentration Xb was estimated at 12.9 mU/l, which, in 
steady states conditions (when X(t) = Xb, G(t) = Gb , and x1(t) = 
x2(t)=xss), represents ‘a constant insulin infusion rate xss of 
0.017U/h/kg [or 1.2 U/h at 70kg body weight as calculated 
from (3)] that maintains constant glucose level. The CVs 
represent day-to-day variability of the model parameters which 
were estimated in the range of 38 to 79% for insulin sensitivity 
and 27 to 48% for time-to-peak insulin action. Boxplots 
representing the variability of individual day-level estimates of 
SI, tmax,IA and Xb are shown in Fig. S1, OSM Appendix D.  
D. Simulation of 2-Hour Insulin Pump Suspension 
For the purpose of model validation, we performed an in 
silico simulation of an independent clinical trial during which 
the insulin pump basal infusion was suspended for 2 hours 
followed by insulin infusion at 1U/h for another 2 hours over 99 
nights in 17 people with T1D [16]. We simulated glycemic 
changes during and after the 2-hour pump suspension using the 
proposed glucose-insulin model and adopting 96 estimated 
day-level parameter sets randomly chosen from the 8 tested 
participants (12 day-level parameter sets from each subject).    
The comparison between the simulated and published 
clinical results shown in Fig.S2, OSM Appendix E, 
demonstrates comparable changes in glucose concentration at 
2h (end of the 2-hour insulin suspension) and at 4h (2 hours 
after resumption of insulin delivery) including the 
between-subject and between-night variability.    
IV. DISCUSSION 
To our knowledge, the presented insulin-glucose regulation 
model is the first to describe frequently measured sensor 
glucose data in adults with T1D over a prolonged period of up 
 
                 Fig. 3. Weighted residuals (difference between model-predicted and measured CGM values divided by the measurement error) (median [IQR]).    
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to 84 days. We investigated a Bayesian hierarchical modelling 
approach to estimate subject-level and within-subject 
day-to-day model parameters including insulin sensitivity, 
time-to-peak insulin action, time-to-peak gut absorption, and 
carbohydrate bioavailability. The model quantified 
between-day variability of the key physiological parameters. 
The proposed mathematical model comprises five linear 
differential equations and is of moderate complexity with an 
aim to capture essential features of glucose-insulin dynamics 
and, at the same time, guarantee applicability to the rich 
datasets. The results obtained from eight study participants’ 
datasets not only show the physiological plausibility of 
estimated model parameters (Table I) and good model fit (Figs. 
2 and 3), but also the model’s ability to reproduce published 
clinical results (OSM Fig. S1). 
Previous studies successfully demonstrated applications of 
the Bayesian hierarchical framework in various biomedicine- 
or physiology-related dynamic systems [26-31] including the 
well-known ‘minimal model’ describing the glucose-insulin 
kinetics [26, 28]. Important advantages of using the Bayesian 
hierarchical approach is that it allows each subset to ‘borrow 
strength’ from the likelihood contributions of other subsets via 
their joint influence on the estimate of the unknown ‘joint 
distribution’ of parameters, especially under missing data 
scenarios. The multi-day datasets utilized in the present 
analyses enabled us to implement the hierarchical structure 
facilitating the information flow between days and thus 
increasing the credibility of the estimated day-level and 
subject-level parameters. 
Our model of glucose-insulin regulation consists of five 
compartments and three sub-models. The insulin-effect is 
described by a two-compartment model,  simplified from 
previously used three-compartment [12, 14]  to avoid 
identifiability issues due to the lack of plasma insulin 
concentration measurements. The meal absorption dynamics is 
represented by a two compartment model similar to one used in 
a previously published simulation model [7]. As no information 
pertaining to the meal contents was provided which may 
prompt different meal absorption patterns [32], when fitting the 
data, each consumed meal was assumed to have its own 
time-to-peak of maximum absorption tmax,G and bioavailability 
AG. The glucose dynamics is described by a single 
compartment with insulin-dependent glucose utilization 
assumed as linear, assumption also recently adopted by 
Magdelaine et al. [11]. In addition, a glucose self-regulation 
parameter K was incorporated into the model which allowed the 
glucose level to be driven towards a basal state Gb. This 
self-regulation effect may represent renal clearance of glucose 
at high glucose concentration [33] or counter-regulatory 
hormone effect at low glycaemia [34], an important but omitted 
component in previously published models.  
The reported results support the use of the model in in silico 
testing of glucose controllers. For each virtual subject, with 
identified day-level parameter set, the presented model enables 
simulations of long-term study reflecting the day-to-day 
variability in the individual physiology. A clear benefit of using 
the current model in the simulation environment is that due to 
its linearity, the insulin effects on the glucose concentrations 
can be separated out from the full analytical solution. Thus, 
simulations can be performed fast by separating the meal effect 
and re-evaluating glycemic changes stimulated by different 
insulin dosing schemes advised by different glucose 
controllers.  
The main strength of the present study is its novelty in 
characterizing day-to-day variability of physiological 
parameters through the use of a large dataset collected over 
84days. Identification of the presented model only requires 
standard clinical data (CGM levels, insulin dose and amount of 
carbohydrate contents) to be collected without the need of 
glucose tracer or plasma insulin concentration data which are 
utilized by more complex models [12, 13]. The long-term 
model proposed by Magdelaine et al. [11] used the same type of 
clinical data but only described CGM readings for two days and 
assumed identical parameter values between-days. Another 
advantage of adopting the proposed model is the availability of 
the closed-form solution speeding up the parameter estimation 
process especially when using the Bayesian inference and 
MCMC methods.  
However, as with all modelling efforts, there are limitations. 
The relatively simple model structure does not currently take 
into account diurnal variations. In an attempt to capture diurnal 
variations in the model parameters and potential influences 
resulting from other factors, such as physical activities and 
stress levels, we tested the integration of an autoregressive 
model into the residual errors in our preliminary analyses (data 
not shown). However, parameter estimation became notably 
(3-5 times) protracted and posterior model identifiability issues 
became apparent. Computational speed and memory 
considerations prevented us from including subject-level 
domain as another layer in our hierarchical analysis. Having 
such a layer might have led to increased accuracy of population 
parameter estimates and could be implemented through a 
two-stage approach as described recently [35]. Nonetheless, 
these limitations do not diminish the major achievements of our 
modelling approach. 
V. CONCLUSION 
In conclusion, the present study demonstrates the feasibility 
of a new model to represent 12-week glucose-insulin 
interactions within a Bayesian hierarchical framework. The 
day-to-day variability of physiological parameters was assessed 
quantitatively. The model could be implemented in an in silico 
testing environment to simulate realistic data-informed 
long-term closed-loop insulin delivery trials and to aid the 
development of closed-loop systems for home use. Further 
investigations are warranted.  
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